Therapeutic Approaches to Opioid Use Disorder: What is the Current Standard of Care?

References

• Brady K, Levin F, Galanter M, Kleber H. The American Psychiatric Publishing Textbook of Substance Use Disorder Treatment. 6th ed. American Psychiatric Publishing; 2021.
   Google Scholar
• Strang J, Volkow ND, Degenhardt L, et al. Opioid use disorder. Nat Rev Dis Primer. 2020;6(1):3. doi:10.1038/s41572-019-0137-5
   PubMed Web of Science ®Google Scholar
• Kampman K, Jarvis M. American society of addiction medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358–367. doi:10.1097/ADM.0000000000000166
   PubMed Web of Science ®Google Scholar
• Miller W, Rollnick S. Motivational Interviewing: Helping People Change. 3rd ed. Guilford Press; 2013.
   Google Scholar
• Agerwala SM, McCance-Katz EF. Integrating screening, brief intervention, and referral to treatment (SBIRT) into clinical practice settings: a brief review. J Psychoactive Drugs. 2012;44(4):307–317. doi:10.1080/02791072.2012.720169
   PubMed Web of Science ®Google Scholar
• Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. Lancet. 2019;393(10182):1760–1772. doi:10.1016/S0140-6736(18)33078-2
   PubMed Web of Science ®Google Scholar
• Compton WM, Valentino RJ, DuPont RL. Polysubstance use in the U.S. opioid crisis. Mol Psychiatry. 2021;26(1):41–50. doi:10.1038/s41380-020-00949-3
   PubMed Web of Science ®Google Scholar
• Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiatry. 2019;76(2):208–216. doi:10.1001/jamapsychiatry.2018.3126
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM–5). 5th ed. American Psychiatric Association; 2013.
   Google Scholar
• Mee-Lee D. The ASAM Criteria: Treatment Criteria for Addictive, Substance-Related, and Co-Occuring Conditions. 3rd ed. 2013.
   Google Scholar
• Olsen A, Dwyer R, Lenton S. Take-home naloxone in Australia and beyond. Drug Alcohol Rev. 2018;37(4):437–439. doi:10.1111/dar.12700
   PubMed Web of Science ®Google Scholar
• Buresh M, Gicquelais RE, Astemborski J, Kirk GD, Mehta SH, Genberg BL. Fatal overdose prevention and experience with naloxone: a Cross-Sectional Study from a community-based cohort of people who inject drugs in Baltimore, Maryland. PLoS One. 2020;15(3):e0230127. doi:10.1371/journal.pone.0230127
   PubMed Web of Science ®Google Scholar
• Kerensky T, Walley AY. Opioid overdose prevention and naloxone rescue kits: what we know and what we don’t know. Addict Sci Clin Pract. 2017;12(1):4. doi:10.1186/s13722-016-0068-3
   PubMed Web of Science ®Google Scholar
• Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med. 2014;8(3):153–163. doi:10.1097/ADM.0000000000000034
   PubMed Web of Science ®Google Scholar
• Kosten TR, Baxter LE. Review article: effective management of opioid withdrawal symptoms: a gateway to opioid dependence treatment. Am J Addict. 2019;28(2):55–62. doi:10.1111/ajad.12862
   PubMed Web of Science ®Google Scholar
• Sigmon SC, Bisaga A, Nunes EV, O’Connor PG, Kosten T, Woody G. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. Am J Drug Alcohol Abuse. 2012;38(3):187–199. doi:10.3109/00952990.2011.653426
   PubMed Web of Science ®Google Scholar
• Jones CM, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug Alcohol Depend. 2019;197:78–82. doi:10.1016/j.drugalcdep.2018.12.030
   PubMed Web of Science ®Google Scholar
• Donroe JH, Bhatraju EP, Tsui JI, Edelman EJ. Identification and management of opioid use disorder in primary care: an update. Curr Psychiatry Rep. 2020;22(5):23. doi:10.1007/s11920-020-01149-0
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. World Health Organization. Available from: https://www.who.int/substance_abuse/publications/9789241547543/en/. Accessed March 28, 2021.
   Google Scholar
• Shulman M, Wai JM, Nunes EV. Buprenorphine treatment for opioid use disorder: an overview. CNS Drugs. 2019;33(6):567–580. doi:10.1007/s40263-019-00637-z
   PubMed Web of Science ®Google Scholar
• Bentzley BS, Barth KS, Back SE, Book SW. Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes. J Subst Abuse Treat. 2015;52:48–57. doi:10.1016/j.jsat.2014.12.011
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O’Connor PG. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence. JAMA Intern Med. 2014;174(12):1947–1954. doi:10.1001/jamainternmed.2014.5302
   PubMed Web of Science ®Google Scholar
• Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003;70(2 Suppl):S59–77. doi:10.1016/s0376-8716(03)00060-7
   PubMed Web of Science ®Google Scholar
• TIP 63: medications for opioid use disorder - full document | SAMHSA publications and digital products. Available from: https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document/PEP20-02-01-006. Accessed March 28, 2021.
   Google Scholar
• Lee JD, Grossman E, DiRocco D, Gourevitch MN. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med. 2009;24(2):226–232. doi:10.1007/s11606-008-0866-8
   PubMed Web of Science ®Google Scholar
• Cunningham CO, Giovanniello A, Li X, Kunins HV, Roose RJ, Sohler NL. A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions. J Subst Abuse Treat. 2011;40(4):349–356. doi:10.1016/j.jsat.2010.12.002
   PubMed Web of Science ®Google Scholar
• Gunderson EW, Wang X-Q, Fiellin DA, Bryan B, Levin FR. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial. Addict Behav. 2010;35(5):537–540. doi:10.1016/j.addbeh.2010.01.001
   PubMed Web of Science ®Google Scholar
• Lee JD, Vocci F, Fiellin DA. Unobserved “home” induction onto buprenorphine. J Addict Med. 2014;8(5):299–308. doi:10.1097/ADM.0000000000000059
   PubMed Web of Science ®Google Scholar
• Oesterle TS, Kolla B, Risma CJ, et al. Substance use disorders and telehealth in the COVID-19 pandemic era: a new outlook. Mayo Clin Proc. 2020;95(12):2709–2718. doi:10.1016/j.mayocp.2020.10.011
   PubMed Web of Science ®Google Scholar
• Oesterle TS, Thusius NJ, Rummans TA, Gold MS. Medication-assisted treatment for opioid-use disorder. Mayo Clin Proc. 2019;94(10):2072–2086. doi:10.1016/j.mayocp.2019.03.029
   PubMed Web of Science ®Google Scholar
• Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: Treatment Improvement Protocol (TIP) series, No. 40; 2004. Available from: https://www.ncbi.nlm.nih.gov/books/NBK64245/. Accessed May 27, 2021.
   Google Scholar
• Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med. 2019;13(2):93–103. doi:10.1097/ADM.0000000000000457
   PubMed Web of Science ®Google Scholar
• Jakubowski A, Fox A. Defining low-threshold buprenorphine treatment. J Addict Med. 2020;14(2):95–98. doi:10.1097/ADM.0000000000000555
   PubMed Web of Science ®Google Scholar
• Samples H, Williams AR, Crystal S, Olfson M. Impact of long-term buprenorphine treatment on adverse health care outcomes in medicaid. Health Aff. 2020;39(5):747–755. doi:10.1377/hlthaff.2019.01085
   PubMed Web of Science ®Google Scholar
• Dalsbø TK, Steiro A, Strømme H, Reinar LM. Effectiveness of Tapering from Methadone or Buprenorphine Maintenance Treatment Compared to Traditional Maintenance Treatment for People with Opiate Addiction: Systematic Review. Norwegian Institute of Public Health; 2017.
   Google Scholar
• Lee JD, Nunes EV, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309–318. doi:10.1016/S0140-6736(17)32812-X
   PubMed Web of Science ®Google Scholar
• Jarvis BP, Holtyn AF, Subramaniam S, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addict. 2018;113(7):1188–1209. doi:10.1111/add.14180
   PubMed Web of Science ®Google Scholar
• Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med. 2000;67(5–6):347–364.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2003;2:CD002209. doi:10.1002/14651858.CD002209
   PubMedGoogle Scholar
• Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with methadone for opioid dependence: a meta-analytical study. Nord J Psychiatry. 2007;61(4):288–295. doi:10.1080/08039480701415251
   PubMed Web of Science ®Google Scholar
• Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622. doi:10.1001/jamanetworkopen.2019.20622
   PubMed Web of Science ®Google Scholar
• Dugosh K, Abraham A, Seymour B, et al. Review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med. 2016;10(2):91–101. doi:10.1097/ADM.0000000000000193
   Web of Science ®Google Scholar
• Carroll KM, Onken LS. Behavioral therapies for drug abuse. Am J Psychiatry. 2005;162(8):1452–1460. doi:10.1176/appi.ajp.162.8.1452
   PubMed Web of Science ®Google Scholar
• Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008;165(2):179–187. doi:10.1176/appi.ajp.2007.06111851
   PubMed Web of Science ®Google Scholar
• White WL. Addiction recovery mutual aid groups: an enduring international phenomenon. Addict. 2004;99(5):532–538. doi:10.1111/j.1360-0443.2004.00684.x
   PubMed Web of Science ®Google Scholar
• Galanter M, White WL, Hunter BD. Cross-cultural applicability of the 12-step model: a comparison of narcotics anonymous in the USA and Iran. J Addict Med. 2019;13(6):493–499. doi:10.1097/ADM.0000000000000526
   PubMed Web of Science ®Google Scholar
• Kelly JF. Is alcoholics anonymous religious, spiritual, neither? Findings from 25 years of mechanisms of behavior change research. Addict. 2017;112(6):929–936. doi:10.1111/add.13590
   PubMed Web of Science ®Google Scholar
• Joudrey PJ, Howell BA, Nyhan K, et al. Reporting of substance use treatment quality in United States adult drug courts. Int J Drug Policy. 2020;90:103050. doi:10.1016/j.drugpo.2020.103050
   PubMed Web of Science ®Google Scholar
• Tran TH, Griffin BL, Stone RH, Vest KM, Todd TJ. Methadone, buprenorphine, and naltrexone for the treatment of opioid use disorder in pregnant women. Pharmacotherapy. 2017;37(7):824–839. doi:10.1002/phar.1958
   PubMed Web of Science ®Google Scholar
• Minozzi S, Amato L, Bellisario C, Davoli M. Maintenance treatments for opiate -dependent adolescents. Cochrane Database Syst Rev. 2014;(6):CD007210. doi:10.1002/14651858.CD007210.pub3
   PubMed Web of Science ®Google Scholar
• Oesterle TS, Kolla BP, Rummans TA, Gold MS. Medication-assisted therapies for opioid use disorders in patients with chronic pain. J Neurol Sci. 2020;411:116728. doi:10.1016/j.jns.2020.116728
   PubMed Web of Science ®Google Scholar
• Harrison TK, Kornfeld H, Aggarwal AK, Lembke A. Perioperative considerations for the patient with opioid use disorder on buprenorphine, methadone, or naltrexone maintenance therapy. Anesthesiol Clin. 2018;36(3):345–359. doi:10.1016/j.anclin.2018.04.002
   PubMedGoogle Scholar